Page 1 | Search Results | Blood | American Society of Hematology

1-10 of 10

Sort by

Sort Order Select

Journal Articles

Comparable Outcomes of Point-of-Care and Commercial CD19 CAR-T Therapies: A Patient-Matched Analysis in Large B-Cell Lymphoma

Blood (2024) 144 (Supplement 1): 608.

https://doi.org/10.1182/blood-2024-207638

Published: 2024

Journal Articles

CAR-Tography: Longitudinal Mapping of CAR-T Toxicities across B-Cell Malignancies Reveals Biologically Distinct and Prognostically Relevant Toxicity Phenotypes

Blood (2024) 144 (Supplement 1): 912.

https://doi.org/10.1182/blood-2024-203520

Published: 2024

Journal Articles

Predictors of Cytokine Release Syndrome and Neurotoxicity in Patients with Large B-Cell Lymphoma and Their Impact on Survival

Blood (2023) 142 (Supplement 1): 355.

https://doi.org/10.1182/blood-2023-181181

Published: 2023

Journal Articles

Response Rates of Extra-Nodal Diffuse Large B Cell Lymphoma to CD19-CAR T Cells - a Real Word Retrospective Multi-Center Study

Blood (2022) 140 (Supplement 1): 3816–3817.

https://doi.org/10.1182/blood-2022-165149

Published: 2022

Journal Articles

Prognostic Impact of Comorbidities on Outcomes of Patients (pts) with Relapsed or Refractory Large B-Cell Lymphoma (r/r LBCL) Treated with Chimeric Antigen Receptor T-Cell Therapy (CART)

Blood (2022) 140 (Supplement 1): 4636–4638.

https://doi.org/10.1182/blood-2022-169452

Published: 2022

Journal Articles

Mismatch in Sirpα, a Regulatory Protein in Innate Immunity, Is Associated with Outcomes of Allogeneic Stem Cell Transplantation for Lymphoid Malignancies

Rima M. Saliba, Uri Greenbaum, Qing Ma, Samer A. Srour, Gabriela Rondon, Elizabeth J. Shpall, Kai Cao, Richard E. Champlin, Jun Zou

Blood (2021) 138 (Supplement 1): 1804.

https://doi.org/10.1182/blood-2021-150926

Published: 2021

Journal Articles

Gut Bacterial Diversity Associates with Efficacy of Anti-CD19 CAR T-Cell Therapy in Patients with Large B-Cell Lymphoma

Blood (2020) 136 (Supplement 1): 34–35.

https://doi.org/10.1182/blood-2020-136756

Published: 2020

Journal Articles

The Easix (Endothelial Activation and Stress Index) Score Predicts for CAR T Related Toxicity in Patients Receiving Axicabtagene Ciloleucel (axi-cel) for Non-Hodgkin Lymphoma (NHL)

Blood (2020) 136 (Supplement 1): 17–18.

https://doi.org/10.1182/blood-2020-141388

Published: 2020

Journal Articles

Front-Line Treatment with Obinutuzumab ± Chlorambucil for Chronic Lymphocytic Leukemia in Real-World Clinical Practice: Results of a Multinational, Multicenter Study By Eric and Icllsg

Yair Herishanu, MD, Adir Shaulov, MD, Riva Fineman, MD, Sandra Bašić-Kinda, MD, Ariel Aviv, MD, Ewa Wasik-Szczepanek, MD PhD, Ozren Jaksic, MD PhD, Mihnea Zdrenghea, MD, Uri Greenbaum, MD, Inga Mandac, MD, Martin Simkovic, MD PhD, Marta Morawska, MD, Ohad Benjamini, MD, Martin Spacek, MD, Anatoly Nemets, MD, Osnat Bairey, MD PhD, Andrea Visentin, MD, Rosa Ruchlemer, MD, Luca Laurenti, MD, Oana Stanca Ciocan, MD, Michael Doubek, MD PhD, Lev Shvidel, MD, Nagib Deli, MD, Fatima Miras Calvo, MD, Anne De Meûter, Maria Dimou, MD PhD, Francesca Romana Mauro, MD, Marta Coscia, MD PhD, Horia Bumbea, MD PhD, Szász Róbert, Tamar Tadmor, MD, Odit Gutwein, Massimo Gentile, Lydia Scarfo, MD, Alessandra Tedeschi, MD, Paolo Sportoletti, Eva Gimeno Vázquez, Juan Marquet Palomanes, MD, Sarit Assouline, MD, Maria Papaioannou, Andrei Breaster, MD, Luciano Levato, MD, Michael Gregor, MD, Gian Matteo Rigolin, MD, Javier Loscertales, MD, Angeles Medina Perez, MD, Marten R. Nijziel, MD PhD, Viola Maria Popov, MDPhDMSc, Rosa Collado, MD, Irma Slavutsky, Shai Levi, MSc, Aaron Polliack, MD, Paolo Ghia, MD PhD

Blood (2019) 134 (Supplement_1): 1766.

https://doi.org/10.1182/blood-2019-122309

Published: 2019

Journal Articles

Decreased Iron Overload and Oxidative Stress in Transfusion Dependent Patients with Myelodysplastic Syndromes (MDS) with the Oral Iron Chelator Deferiprone

Drorit Merkel, MD, Shelly Soffer, Kalman Filanovsky, MD, Andrei Braester, MD, Eitan Fibach, PhD, Mutaz Mohammad Dana, Yishay Ofran, MD, Uri Greenbaum, MD, Arnon Nagler, MD, Moshe Mittelman, MD

Blood (2018) 132 (Supplement 1): 4381.

https://doi.org/10.1182/blood-2018-99-115157

Published: 2018

NARROW

Comparable Outcomes of Point-of-Care and Commercial CD19 CAR-T Therapies: A Patient-Matched Analysis in Large B-Cell Lymphoma

CAR-Tography: Longitudinal Mapping of CAR-T Toxicities across B-Cell Malignancies Reveals Biologically Distinct and Prognostically Relevant Toxicity Phenotypes

Predictors of Cytokine Release Syndrome and Neurotoxicity in Patients with Large B-Cell Lymphoma and Their Impact on Survival

Response Rates of Extra-Nodal Diffuse Large B Cell Lymphoma to CD19-CAR T Cells - a Real Word Retrospective Multi-Center Study

Prognostic Impact of Comorbidities on Outcomes of Patients (pts) with Relapsed or Refractory Large B-Cell Lymphoma (r/r LBCL) Treated with Chimeric Antigen Receptor T-Cell Therapy (CART)

Mismatch in Sirpα, a Regulatory Protein in Innate Immunity, Is Associated with Outcomes of Allogeneic Stem Cell Transplantation for Lymphoid Malignancies

Gut Bacterial Diversity Associates with Efficacy of Anti-CD19 CAR T-Cell Therapy in Patients with Large B-Cell Lymphoma

The Easix (Endothelial Activation and Stress Index) Score Predicts for CAR T Related Toxicity in Patients Receiving Axicabtagene Ciloleucel (axi-cel) for Non-Hodgkin Lymphoma (NHL)

Front-Line Treatment with Obinutuzumab ± Chlorambucil for Chronic Lymphocytic Leukemia in Real-World Clinical Practice: Results of a Multinational, Multicenter Study By Eric and Icllsg

Decreased Iron Overload and Oxidative Stress in Transfusion Dependent Patients with Myelodysplastic Syndromes (MDS) with the Oral Iron Chelator Deferiprone

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only